Full Length Research Paper

Structural features in neuropsin as potential target for pharmacological inhibition in brain diseases

Reinaldo Barros Geraldo^{1,4}, Paula Campello Costa Lopes², Carlos Rangel Rodrigues³, Russolina Benedeta Zingali⁴, Helena C. Castro¹

¹Antibiotics Laboratory, Biochemistry, and Molecular Modeling Study (LABioMol), Department of Molecular Cell Biology, Institute of Biology, CEG - Universidade Federal Fluminense, Rio de Janeiro, Brazil.

²Neural Neuroplasticity Laboratory, Department of Neurobiology, Institute of Biology, CEG - Universidade Federal Fluminense, Rio de Janeiro, Brazil.

³Laboratory of Molecular Modeling and QSAR (ModmolQSAR), Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.

⁴Institute of Medical Biochemistry, Structural Biology Program, CCS, UFRJ, CEP 21941-590, Rio de Janeiro, RJ, Brazil.

Accepted 21 February, 2013

Neuropsin is a serine-protease produced by neurons and glial cells that is directly involved in learning and memory processes. This enzyme presents an important role in brain diseases such as epilepsy and Alzheimer disease. In this work we reviewed several aspects about this enzyme including structure, biological activity and its role in the central nervous system. We also compared neuropsin with other serine-proteases such as trypsin, an enzyme found in digestive and brain systems, thrombin, a coagulation cascade enzyme, and Lm-TL of a thrombin-like enzyme present in *Lachesis muta* venom that affects the prey central nervous system, among others, using bioinformatic tools. The analysis of the structural features of neuropsin and of these enzymes that present different and specific biological activities despite their high homology degree may help on designing selective inhibitor for treating several diseases including brain disorders.

Key words: Neuropsin, serine proteases, plasticity, homology, docking.

INTRODUCTION

Serine-proteases are hydrolyses that use the serine 195 hydroxyl group to cleave amidic linkage in peptides and proteins (Barrett, 1995). These enzymes belong to a large family composed by different sub-families, classified in accord to their crystal structure (Rao et al., 1998; Krem and Di Cera, 2000). Among them, the subfamily that is represented by trypsin, a pancreatic digestive enzyme (Perona and Craik, 1995; Perona and Craik, 1997), and includes mesotrypsin/trypsin neurogenic IV, а inflammation and pain modulator (Knecht and Adamesi, 2007); thrombin, a coagulation cascade enzyme (Carter, 2005); Lm-TL, a thrombin-like enzyme from Lachesis muta muta venom (Castro, 2001; Castro, 2004); urokinase plasminogen activator (u-PA); an

enzyme involved in cancer dissemination and metastasis (Andreasen et al., 2000; Zeslawska et al., 2000); protease involved neurosin, а in neurodegenerative disease (i.e. Alzheimer disease, Parkinson disease and Multiple sclerosis) (Wang et al., 2008) and neuropsin, expressed in neuronal and glial cells and involved in learning and memory processes and multiple sclerosis (Terayama et al., 2005). Neuropsin has been described as participating on different processes, such cell adhesion, migration, proliferation and motility (Chen et al., 1995; Underwood et al., 1999; Shiosaka, 2004; Kishi et al., 1999). In this work, we briefly reviewed important aspects about neuropsin including its role in central nervous system, molecular structure and biologic activity. We also evaluated the activity-structure relationship of this

enzyme with a substrate by performing a theoretical docking analysis with the tri-peptide Val-Pro-Arg

^{*}Corresponding author: E-mail:hcastrorangel@yahoo.com.br. 55-21-26299954



Figure 1. Theoretical mechanism scheme of neuropsin action. Pro-neuropsin is secreted and activated by neuronal NMDA receptor stimuli, the neuropsin may act in two ways: A)fibronectin degradation, and/or B) L1 cleavage in cell adhesion molecule (CAM) into a presynaptic neuron. (C) Neuropsin 3D-structure highlights the handle glycosylation and position of catalytic site, typical of the trypsin and kalicrein family. D) The neuropsin catalytic site showing the catalytic triad, Asp189 (S1), Pro95 (S2), the Lys175 (S3) and lle41 (S1').

(Shimizu et al., 1998). Finally, to identify some characteristics related to its distinct biological functions we compared this enzyme with, six homologous serine-

proteases that are important in some physiological and pathological processes in the organism, including trypsin, trypsin IV, thrombin, neurosin, Lm-TL and u-PA.

METHODOLOGY

The literature search since 1990 was performed in the Pubmed (http://www.ncbi.nlm.nih.gov/pubmed), and ScienceDirect (<u>http://www</u>. sciencedirect. com/) database using thas keywords neuropsin and K8K, with the subheadings expression, function, synthesis and activation.

RESULTS

Neuropsin: origin and function

Neuropsin, also called kallikrein 8 (KLK8) (Magklara et al., 2001; Kishi et al., 2003; Yousef et al., 2003), brain serine-protease 1 (BSP1) (Davies et al., 2001), or tumor-associated differentially expressed gene-14 (TAG-14) (Cane et al., 2004) is highly expressed in hippocampal pyramidal neurons, in the lateral and basolateral nucleus of the amygdala, and in other limbic system areas (Chen et al., 1995; Davies et al., 1998), suggesting their role in neuroplasticity.

Ontogeny study on mice pointed to the involvement of the neuropsin in embryonic cell differentiation, migration, axonal outgrowth and synaptogenesis (Suzuki et al., 1995). Indeed, during early stages of development, this enzyme hydrolyze extracellular matrix components and regulates neural circuits formation. In adults, its importance includes not only the regulation of survival and cellular proliferation, but also the activation and processing of neuropeptide, hormones and growth factors. (Davies et al., 2001). At synaptic level, neuropsin has been implicated in Schaffer-collateral long term potentiation, since studies using recombinant neuropsin showed a potential impact for NP. In LTP it might be a major effecter situated upstream of a signaling cascade for synaptic plasticity. r-NP alone can occlude TBS-induced LTP and induce LTP-associated phosphorylation of the AMPA receptor. In particular, the role of NP in LTP is critical in its early phase, since loss of NP or inhibition of NP completely abolished E-LTP induced by a single tetanus. (Komai et al., 2000; Tamura et al., 2006). The proteolysis contributes to the remodeling of the neural contacts during learn and consolidation of the memory (Bailey and Kandel, 1993). It has also been shown that neuropsin could regulate neuronal plasticity through cleavage of fibronectin, a protein of the extracellular matrix (Figure 1) (Shimizu et al., 1998; Tani et al., 2001) or through cellular adhesion L1 (L1-CAM), located in the pre-synaptic neurons of rats hippocampus (Figure 1) (Matsumoto-Miyai et al., 2003). Studies using neuropsin-deficient mice revealed a decrease in synaptic transmission in the stratum radiatum of hippocampus (Hirata et al., 2001), whereas patients with Alzheimer disease present an increase in mRNA levels for this enzyme compared to normal

individuals. In addition, models for epilepsy and neuronal plasticity present an increase in neuropsin expression and a progressive variation in the electric activity and behavior of animals (kindling epilepsy) (Chen et al., 1995; Okabe et al., 1996; Tomizawa et al., 1999). Interestingly, literature suggests that the inhibition of neuropsin may be useful in the epilepsy treatment, since it may affect the episodes in development (Momota et al., 1998; Oka et al., 2002). In addition to the central nervous system, the mRNA that codifies neuropsin was found in normal and pathological mouse skin (i.e. psoriasis vulgaris and squamous cell carcinoma). Although the mechanism of neuropsin action is still unknown, it has been suggested that this enzyme could participate in cellular differentiation. Assays using neuropsin-deficient mice showed that this enzyme is involved in skin differentiation, but not in migration and desquamation. studies using morphological comparison These between neuropsin -/- and +/+ mice revealed an irregular cells alignment in the thickened epidermis obvious on day 2 after irradiation in the wild-type mice. Differently, it was prolonged for at least 2 days in the neuropsin-deficient mice (Suzuki et al., 1995; Matsumoto-Miyai et al., 2002; Kirihara et al., 2003). Its profile involves the process of epidermis keratinizing in mucous membrane and hair (Chen et al., 1998; Kuwae et al., 1998). Moreover, the presence of the neuropsin mRNA in pregnant uterus, suggests its participation in the decidual process, where occurs the proteolysis of some proteins of cellular adhesion, such as fibronectin (Chen et al., 1998; Kitagawa et al., 2002).

Neuropsin: synthesis and activation

The neuropsin is released in the extracellular matrix, as an inactive precursor (pro-neuropsin), which is activated by removal of four amino acids residues in the aminoterminal region identified as Glu-Gly-Ser-Lys in mouse and Glu-Gln-Asp-Lys in humans (Shimizu et al., 1998). According to the literature, neuropsin secretion mechanism involves potassium and calcium ions, which induces its expression in Neuro2a cells. The intracellular neuropsin signals were localized as punctate granules in neuronal cell bodies and neurites. After secretion, the extracellular periplasmic localization of neuropsin is probably due to binding of the enzyme to the cell surface molecules including L1 and fibronectin bound to integrin (Nakamura et al., 2006; Oka et al., 2002). Using an in vivo LTP approach, literature suggests that the mechanism of neuropsin activation involves N-methyl-D-aspartate receptor (NMDAr) activation, since this process is inhibited by DL-2amino-5-phosphonovaleric acid (AP-5), a NMDA receptor antagonist. Likewise, NMDAr activation or inhibition seems to respectively activate or blockade the

304

	16 20	30	40	5	0 57	60	70	80
HNeuropsin1-	VLGGHECQPH	ISQPWQAALFQ	GQQLL	CGGVLVGG	NWVLTAAHC	ККРКҮТ-	VRLGDHSLQ	2NKDGPEQEIPVVQ
HNeuropsin2-	VLGGHECQPH	ISQPWQAALFQ	GQQLL	CGGVLVGG	NWVLTAAHC	ККРКҮТ-	VRLGDHSLQ	2NKDGPEQEIPVVQ
MNeuropsin-	ILEGRECIPH	ISQPWQAALFQ	-GERLI	CGGVLVGD	RWVLTAAHC	KKQKYS-	VRLGDHSLQ	QSRDQPEQEIQVAQ
HNeurosin-	LVHGGPCDKI	SHPYQAALYT	SGHLL	CGGVLIHP	LWVLTAAHC	KKPNLQ-	VFLGKHNLF	RQRESSQEQ-SSVVR
Hu-PA-	IIGGEFTTIE	NQPWFAAIYRR	IRGGSVTYV	CGGSLISP	CWVISATHC	FIDYPK	KEDYIVYLGRSRL-	NSNTQGE-MKFEVE
Lm-TL-	VIGGDECNIN	IEHRFLVALYDGI	SGTFL	CGGTLINQ	EWVLTAQHC	NRSLMN	IYLGMHNKN	IVKFDDEQRRYPKK
HTrypsinIV-	IVGGYTCEEN	ISLPYQVSLN	SGSHF	CGGSLISE	QWVVSAAHC	YKTRIQ-	VRLGEHNIP	VLEGNEQFINAVK
HTrypsin-	IVGGYTCGAN	TVPYQVSLN	SGYHF	CGGSLINS	QWVVSAAHC	YKSGIQ-	VRLGEDNIN	IVVEGNEQFISASK
HThrombin-	IVEGSDAEIG	MSPWQVMLFRKS	SPQELL	CGASLISD	RWVLTAAHC	LLYPPWDKNFI	ENDLLVRIGKHSR	RYERNIEKISMLEK
	:: *	: : :		**: *:	**::* **		: :*	*
	90	100 102	110	120		130 1	40	150 160
HNeuropsini-	SIPHPCYNSS	DVEDHNHDLML	QLRDQASL	GSKVKPIS	LADH	TOPGORCTVS	GWGTVTSPF	RENFPDTLNCAEVKIFPQKK
HNeuropsin2-	SIPHPCYNSS	DVEDHNHDLML	QLRDQASL	GSKVKPIS	LADH	TOPGORCTVS	GWGTVTSPF	RENFPDTLNCAEVKIFPQKK
MNeuropsin-	SIQHPCYNNS	INPEDHSHDIML	RLQNSANL	GDKVKPVQ	LANL	PRVGQKCIIS	GWGTVTSPQ	2ENFPNTLNCAEVKIYSQNK
HNeurosin-	AVIHPDYDAA	SHDQDIMLI	RLARPAKL	SELIGHTA	LERD	SANTISCHII	GWGKTADG-	DEPDTIQCAVIHLVSREE
Hu-PA-	NLILHKDYSA	DTLAHHNDIALI	KIRSKE-G	RCAQPSRT	IQTICLPSM	INDPQFGTSCE	ITGFGKENSTI	OYLYPEQLKMTVVKLISHRE
Lm-TL-	KYFFRCNF	NFTKWDEDIRL	RPVRFSAH	IEPLSLP-	SN	PPSEDSVCRVN	GWGQITSPI	PETLPDVPHCANINLFNYTV
HTrypsinIV-	IIRHPKYNRE	TLDNDIML	KLSSPAVI	NARVSTIS	LPTA	PPAAGTECLIS	GWGNTLSFC	GADYPDELKCLDAPVLTQAE
HTrypsin-	SIVHPSYNSK	TLNNDIML	KLKSAASL	NSRVASIS	LPTS	CASAGTQCLIS	GWGNTKSSC	STSYPDVLKCLKAPILSDSS
HThrombin-	IYIHPRYNWF	ENLDRDIAL	KLKKPVAF	SDYIHPVC	LPDRETAAS	LLQAGYKGRVI	GWGNLKETWTANVO	GKGQPSVLQVVNLPIVERPV
		::					*	* ::
	170	190	190	105 200		210	220 230	240
HNeuropsin1-	CEDAYPGOIT	DGMVCAGSSK	GADTCO	GDSGGPLV	CDGA	-LOGITSWGSE	PCGRSDKPGVYTNI	CRYLDWIKKIIGSKG
HNeuropsin2-	CEDAYPGOIT	DGMVCAGSSK	GADTCO	GDSGGPLV	CDGA	-LOGITSWGSE	PCGRSDKPGVYTNI	CRYLDWIKKIIGSKG
MNeuropsin-	CERAYPGKIT	EGMVCAGSSN	GADTCO	GDSGGPLV	CDGM	-LOGITSWGSE	PCGKPEKPGVYTKI	CRYTTWIKKTMDNRD
HNeurosin-	CEHAYPGOIT	ONMLCAGDEKY-	GKDSCO	GDSGGPLV	CGDH	-LRGLVSWGNI	PCGSKEKPGVYTN	CRYTNWIOKTIOAK
Hu-PA-	COOPHYYGSE	VTTKMLCAADPO	W-KTDSCO	GDSGGPLV	CSLOGRM	TLTGIVSWGRG	-CALKDKPGVYTRV	SHFLPWIRSHTKEENGLAL
Lm-TL-	CRGAYPR-ME	TKVLCAGVLEG-		RDSGGPLI	CNGO	-FOGIVFWGPE	PCAOPDKPGVYTK	FDYLDWIOSVIAGNTTC
HTrvpsinIV-	CKASYPGKIT	NSMFCVGFLEG-	GKDSCO	RDSGGPVV	CNGO	-LOGVVSWGHG	-CAWKNRPGVYTK	YNYVDWIKDTIAANS
HTrypsin-	CKSAYPGOIT	SNMFCAGYLEG-	GKDSCO	GDSGGPVV	CSGK	-LOGIVSWGSG	-CAQKNKPGVYTK	CNYVSWIKQTIASN
HThrombin-	CKDSTRIRIT	DNMFCAGYKPDI	GKRGDACE	GDSGGPFV	MKSPFNNRW	YOMGIVSWGEG	-CDRDGKYGFYTH	FRLKKWIOKVIDOFGE
	*		* *	**** :		*: ***	* ****	**
1								

Figure 2. Primary and secondary alignments of the mouse (M) or Human (H) Type I and type II neuropsin, Neurosin, Lachesis muta - Thrombin like (Lm-TL), Trypsin,thrombin, urokinase plasminogen activator (Hu-PA) and trypsin IV. sequences. Identical amino acids are characterized by asterisks (*), the similar conservative by (:) and similar non-conservative (.). We also can notice the catalytic triad amino acids (H57, D102, S195), S1 subsite (D189), S2 and S3 subsites common to the three neuropsins (S2-S3, Pro95-Lys173) as well as the S1 subsite '(IIe41) of mouse neuropsin and the subsites S2 (Gly216) and S3 (Gly226) of Lm-TL and trypsin. The secondary structure of a-helix structures in red, ß-sheets in blue and random in black were predicted using the program Jpred (http://www.compbio.dundee.ac.uk/www-jpred/submit.html). Numbering is in accordance with trypsin.

conversion of the pro-neuropsin in active enzyme. The activation of NMDA receptor involves the protein kinase activation as calmodulin-dependent kinase II (CaMK II), mitogen-activated protein kinase (MAPK), proteins kinase A and C (PKA and the PKC), suggesting that the activation of the neuropsin could also be related to these proteins activity (Matsumoto-Miyai et al., 2003).

Neuropsin: structure-activity relationship

Currently literature describes two human neuropsin isoforms, homologous to mouse neuropsin called human neuropsin type I (NH-1) and one exclusively expressed in humans, called neuropsin human type II (NH-2) (Figure 2). The NH-2 is more expressed in adults and presents 44 amino acids more than NH-1 (Figure 2) (Li et al., 2004). The comparison of the primary sequence of the NH-1 with the mouse neuropsin shows 72% of similarity (Figure 2), including the presence of a small N-glycosylated region (Mitsui et al 1999; Yoshida et al., 1998). Studies that compared the structure of the NH-2 with the neuropsin of others primates than human point out the origin of this enzyme as a relatively recent event of approximately 18 million years (Li et al., 2004).

The gene that codifies human neuropsin presents six exons and five introns, similarly to the serine-proteases of trypsin subfamily (Yoshida et al., 1998, Yoshida et al., 2000). Neuropsin is also called KLK8 as in human, this gene is codified amongst a set of genes of the kallikrein multigens family (Gan et al., 2000; Diamandis et al., 2000; Clements et al., 2001; Yousef and Diamandis, 2001).

Neuropsin presents 260 amino acids (30 kDa) (Figure 2) and six disulfides bonds, which are conserved in protease family (C_{22} - C_{157} , C_{42} - C_{58} , C_{128} - C_{232} , C_{136} - C_{201} , C_{168} - C_{182} , C_{191} - C_{220}). Neuropsin secondary structures are composed by two α -helices and fourteen β -strands, which form two groups of seven- β -strand. The neuropsin antiparallel β -sheet fold is a typical trypsin-like structural arrangement where the catalytic site geometry guarantee the catalytic triad (H₅₇, D₁₀₂ and S₁₉₅) (Figure 1) (Dodson and Wlodawer, 1998). This enzyme still presents a N-glycosylated loop, called the kallikrein loop, which an Asn-X-Ser sequence that binds to N-acetylglucosamine (NAG) (Figure 1 and 2) (Kishi et al., 2003; Katz et al., 1998; Takahashi et al., 1999).

In this work we performed a comparative study among neuropsin and others six serine-proteases that present



Figure 3. Comparison of Neuropsin structural features. (A) 3D-alignment of the whole structure and (B) the catalytic site of neuropsin, neurosin, trypsin IV, trypsin , thrombin, u-PA and Lm-TL. (C) Comparison of the root mean square deviation (RMSD) value of each structural alignment.

diverse functions in the human organism, including, trypsin, involved in digestion process; trypsin IV, responsible for an edema and inflammatory cell recruitment (Knecht et al., 2007); neurosin, acting in the maintenance of myelination (Bando et al., 2006); thrombin, from coagulation cascade; urokinase-type plasminogen activator (u-PA), involved in cell adhesion, migration, proliferation, motility and metastasis process, and Lm-TL a snake venom thrombin-like enzyme. Since these proteases belong to the same protease subfamily, literature suggests a high degree of structural similarity among neuropsin, u-PA, trypsin and the Lm-TL, although they participate in different biological processes (Perona and Craik 1997; Castro et al., 2001; Castro et al., 2004; Kishi et al., 1999, Perona et al., 1995). Moreover, we investigated the structural characteristics of these seven enzymes (neuropsin, trypsin, trypsin IV, neurosin, thrombin, u-PA and Lm-TL), which is important for establishing its intrinsic specificities. On that purpose we used the crystals structures of neuropsin (PDB1npm), trypsin (PDB1pph), trypsin IV (PDB1h4w), neurosin (PDB1gvl) thrombin (PDB1hxe), and u-PA (PDB1f5I), obtained from Protein

Databank (www.pdb.org), and the theoretical model of the Lm-TL, constructed using program SWISS-MODEL (www.swissmodel.expasy.org) (Castro et al., 2001; Guex and Peitsch, 1997).

The alignment of the primary sequences of mouse neuropsin, human neuropsin type 1 and type 2, human neurosin, human trypsin and human trypsin IV, human thrombin, human u-PA and Lm-TL, using the program CLUSTALW (www.ebi.ac.uk/clustalw) and swissprt spdb-viewer respectively, showed as expected the conservation of the catalytic triad (His57, Asp102 and Ser₁₉₅) and the S1 site (S1=Asp₁₈₉) confirming their experimental preference for basic residues in the chromogenic and protein substrates (arginine or lysine) in the P1 position (R.M.S.D. = 0,2-0,24Å). However, the S2 and S3 positions vary in neuropsin (P_{95} and K_{175}) compared to the other enzymes (G₂₁₆ and G₂₂₆) (Figure 2 and 3). These features, which probably orientate for their different biological activities observed in these enzymes and their different protein targets. Interestingly, the mouse neuropsin primary structure presents a significant homology degree with the others structures (34-73%).



Figure 4. Comparison of the charged regions of neuropsin with other known serine proteases. Several residues (R =Arginine, K = Lysine, H = Histidine, D = Aspartic acid and E = Glutamic Acid) form the positive and negative regions of these proteases (up) that results in different 3D electrostatic potential maps that influence their enzymatic specificity (positive - blue and negative regions - red).

The analysis of the secondary structure of these enzymes revealed the conservation of the two α -helices, and the two groups of β -sheet (Figure 2 and 3). Three disulfides bonds are conserved in all of these enzymes including Cys₄₂ -Cys₅₈, Cys₁₆₈ - Cys₁₈₂ and Cys₁₉₁ - Cys₂₂₀. However they present exclusive bonds such as Lm-TL with Cys₂₂ - Cys₁₅₇, Cys₁₃₆ - Cys₂₀₁, similar neuropsin, neurosin and trypsin and Cys₉₁ - Cys₂₅₀ in the carboxyl-terminal region that is characteristic of snake venom serine-proteases (Castro et al., 2004). Interestingly, neuropsin, neurosin and trypsin have the same disulfide bonds, Cys_{22} - $Cys_{157},\ Cys_{136}$ -Cys₂₀₁ and Cys₁₂₈ - Cys₂₃₂, whereas thrombin presents C₁ -C₁₂₂ and u-PA, Cys₅₀ - Cys₁₁₁ and Cys₁₃₆ - Cys₂₀₁. Trypsin IV presents only five disulfides bonds (Cys₂₂ - Cys₁₅₇, Cys₄₂ -Cys₅₈, Cys₁₃₆ - Cys₂₀₁, Cys₁₆₈ - Cys₁₈₂ and Cys₁₉₁ - Cys₂₂₀), because the amino acids \mbox{Cys}_{128} and \mbox{Cys}_{232} that are substituted by Pro₁₂₈ and Tyr₂₃₂.

As expected, the alignment of the three-dimensional structures of trypsin, trypsin IV, thrombin, u-PA, neurosin and Lm-TL, with neuropsin shows low R.M.S.D. values (0,81Å; 0,83Å; 0,92Å; 1,04Å; 0,86Å and 0,73Å respectively) (Figure 3). However the surfaces of these molecules significantly vary as expect since the electrostatic effects are important factors in determining not only the conformation and stability of proteins in solution, but also its binding to that ligands (Sharp & Honig, 1990; Bajorath *et al.*, 1991). So, the electrostatic potential maps analysis may reveal positive regions, due to presence of basic amino acids as histidine (H), lysine (K) and arginine (R), or with

negative regions, due to acidic amino acids (acid aspartic -D and acid glutamic - E). The electrostatic potential map of the seven enzymes studies herein showed that neuropsin, thrombin, u-PA and Lm-TL present different distribution of the negative and positive regions in their surface explaining once more their different protein target despite their homology (Figure 3). In neuropsin, the positive (*i.e.* K_{59} , K_{60} , K_{62} , K_{161} , K_{167} and R_{170} ,) and negative (*i.e.* E18, E21, E₃₈, E169, E178, D189, D194,) regions are distributed forming positives and negatives patches in protein surface. The neurosin MEPs posses a the negative portion near from the catalytic site (i.e. D185, E₁₈₆, D₁₉₄ and D₂₀₇) and the positive in small regions (K_{15}, K_{18}, K_{24}, K_{60}, K_{70}, R_{74}, R_{233} and K_{240}). In u-PA, the electrostatic potential map are (E₂₀, E₂₅, D₆₀, $D_{93}, D_{97}, D_{102}, E_{110c}, E_{144}, E_{148}, E_{153}, E_{167}, E_{175}, D_{189}, D_{194}$ and D_{223b}) and positive regions (R₃₅, R₃₆, H₃₇).In Lm-TL, two great distinct regions, one negative (D20, E21, E26, D35, D77, D78, D79, D100, E101, D102, E116, E126, D128, E187, D189, D194, D218, D224, D233 and D236) and another one positive (R28, H57, H70, K72, K75, R81, R82, K85, K86, K87, R90, K94, K98, R104, R107, R110, R137, R169, R174, R179, R193, K225 and K230) Thrombin presents a positive sites formed in N-terminal (i.e. R35, K36, R50, R57, K60, R67 and K70) and in C-Terminal (i.e. K202, R206, R221, K224, H230, R233, K235, K236 and K240) and the negative loads mainly in the catalytic sites (i.e. D170,D186b, E186c, D189, E192, D194). Trypsin posses an electropositive map, presenting still small regions negative, next to the catalytic site formed by E70, D76, E77,

E80, D102 D153, E186 and D194 (Figure 2). However, in 280: 2745-9. trypsin IV posses a large electronegative region that posses (E49, E70, E77, E80, D97, E135, D150, D153, D159, E186, D189, D194, D236, D240) and presenting still two regions positive composed by (H40, H57, K60, R66, K74, K87, R90, H91, K93, R96, K107, K156, K169, K175, K188, R193, H217, K222, R224, K230 and K239) (Figure 4). These structural electronic differences suggested that these regions must guide the more complex maps, needing a and complementarities with the perfect alignment macromolecular substrate, different from trypsin and thrombin (Figure 3). The determination of the amino acids of these regions may be important for the development of a more specific inhibitor for these enzymes to identify the interactions of the neuropsin with a small substrate.

CONCLUSION

Neuropsin plays a crucial role in the synaptic plasticity, involved in learning and memory process and pathologies such as epilepsy and Alzheimer's disease. Interesting, currently literature presents neuropsin as a clinical target for the diagnosis or prognostic of diseases such as ovarian cancer.

Therefore, this enzyme could be useful as target for therapeutically action and design of new drugs for treating related pathologies (i.e. multiple sclerosis).

REFERENCES

Andreasen PA, Egelund R, Petersen HH (2000). The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. pp 57(1):25-40.

Bailey CH, Kandel ER (1993). Structural changes accompanying memory storage. Annu Rev Physiol. pp 55: 397-426.

Bajorath J, Kitson DH, Kraut J, Hagler AT. (1991) The electrostatic potential of Escherichia coli dihydrofolate reductase. Proteins Struct Funct Genet pp 11:1-12.

Bando Y, Ito S, Nagai Y, Terayama R, Kishibe M, Jiang YP, Mitrovic B, Takahashi T, Yoshida S (2006). Implications of protease M/neurosin in myelination during experimental demyelination and remyelination. Neurosci Lett. pp 405(3):175-80.

Barrett AJ, Rawlings ND (1995). Families and clans of serine peptidases. Arch Biochem Biophys. pp 318: 247-50.

Cane S, Bignotti E, Bellone S, Palmieri M, Las Casas L, Roman JJ, Pecorelli S, Cannon MJ, O'Brien T, Santin AD. (2004) The novel serine protease tumor-associated differentially expressed aene-14 (KLK8/Neuropsin/Ovasin) is highly overexpressed in cervical cancer. Am. J. Obst. Gyneco. pp 190: 60-6.

Carter WJ, Cama E, Huntington JA (2005). Crystal structure of thrombin bound to heparin. J Biol Chem. Pp

Castro HC, Silva DM, Craik C, Zingali RB. (2001) Structural features of a snake venom thrombin-like enzyme: thrombin and trypsin on a single catalytic platform? Biochim Biophys Acta. pp 1547: 183-95.

Castro HC, Zingali RB, Albuquerque MG, Pujol-Luz M, Rodrigues CR (2004). Snake venom thrombin-like enzymes: from reptilase to now. Cell Mol Life Sci pp 61: 843-56.

Chen Z, Yoshida S, Kate K, Momota Y, Suzuki J, Tanaka T, Ito J, Nishino H, Aimoto S, Kiyama H, Shiosaka S (1995) Expression and Activity-Dependent Changes of a Novel Limbic-Serine Protease Gene in the Hippocampus. J Neurosci. pp 75: 5088-97

Clements J, Hooper J, Dong Y, Harvey T (2001). The expanded human kallikrein (KLK) gene family: Genomic organization, tissue-specific expression and potential functions. Biol Chem. pp 382: 5-14.

Davies B. Kearns IR. Ure J. Davies CH. Lathe R (2001). Loss of Hippocampal Serine Protease BSP1/Neuropsin Predisposes to Global Seizure Activity. J Neurosci. pp 21: 6993-7000.

Davies BJ, Pickard BS, Steel M, Morris RGM, Lathe R (1998). Serine Proteases in Rodent Hippocampus. J Bio Chem. pp 273: 23004-11.

Diamandis EP, Yousef GM, Clements J, Ashworth LK, Yoshida S, Egelrud T, Nelson PS, Shiosaka S, Little S, Lilja H, Stenman UH, Rittenhouse HG, Wain H. (2000) New Nomenclature for the Human Tissue Kallikrein Gene Family. Clin Chem. pp 46: 1855-58

Dodson G, Wlodawer A (1998). Catalytic triads and their relatives. Trends Biochem Sci. pp 23: 347-52.

early processes of memory acquisition and Schaffer collateral long-term potentiation in adult mouse hippocampus in vivo. J Physiol (Lond). pp 570:541-551.

Gan L, Lee I, Smith R, Argonza-Barrett R, Lei H, McCuaig J, et al. (2000). Sequencing and expression analysis of the serine protease gene cluster located in chromosome 19q13 region. Gene. pp 257: 119-30.

Guex N, Peitsch MC (1997) SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modelling. Electrophoresis. pp 18: 2714-23.

Hirata A, Yoshida S, Inoue N, Matsumoto-Miyai K, Ninomiya A, Taniguchi M, Inoue N, Matsumoto-Miyai K, Ninomiva A.

Taniguchi M, Matsuyama T, Kato K, Iizasa H, Kataoka Y, Yoshida N, Shiosaka S. (2001) Abnormalities of Synapses and Neurons in the Hippocampus of Neuropsin-Deficient Mice. Mol Cell Neurosci. 17: 600-10.

Hirotsu S, Mizuno H, Fukuda K, Qi MC, Matsui T, Hamako J, Morita T, Titani K . (2001) Crystal structure of bitiscetin, a von Willebrand factor-dependent platelet aggregation inducer. Biochemistry. 40: 13592-7.

Katz BA, Liu B, Barnes M, Springman EB (1998). Crystal structure of recombinant human tissue kallikrein at 2.0 A resolution. Protein Sci. 7: 875-85.

Kirihara T, Matsumoto-Miyai K, Nakamura Y, Sadayama

T, Yoshida S, Shiosaka S (2003). Prolonged recovery of ultraviolet B-irradiated skin in neuropsin (KLK8)-deficient mice.Br J Dermatol. 149(4):700-6.

Kishi T, Grass L, Soosaipillai A, Shimizu-Okabe C, Diamandis EP (2003). Human Kallikrein 8: Immunoassay Development and Identification in Tissue. Cancer Res. 49: 87-96.

Kishi T, Kato M, Shimizu T, Kato K, Matsumoto K, Yoshida S, et al. (1999). Crystal Structure of Neuropsin, a Hippocampal Protease Involved in Kindling Epileptogenesis. J Biol Chem. 274: 4220-24.

Knecht W, Cottrell GS, Amadesi S, Mohlin J, Skåregärde A, Gedda K, Peterson A, Chapman K, Hollenberg MD, Vergnolle N, Bunnett NW (2007). Trypsin IV or mesotrypsin and p23 cleave protease-activated receptors 1 and 2 to induce inflammation and hyperalgesia. J Biol Chem. 282(36):26089-100.

Knecht, W.; Adamesi S (2007). Trypsin IV or Mesotrypsin and p23 Cleave Protease-activated Receptors 1 and 2 to Induce Inflammation and Hyperalgesia J.Biol. Chem. 282, 26089-26100

Komai S, Matsuyama T, Matsumoto K, Kato K, Kobayashi M, Imamura K, Yoshida S, Ugawa S, Shiosaka S. (2000) Neuropsin regulates an early phase of Schaffer-collateral long termpotention in the murine hippocampus. Eur J Neurosci. 12: 1479-86.

Krem MM, Di Cera, E (2000). Molecular markers of serine-protease evolution. EMBO. 20: 3036-45.

Li Y, Qian Y, Yu X, Wang Y, Dong D, Sun W, et al. (2004) Recent Origin of a Hominoid-Specific Splice Form of Neuropsin, a Gene Involved in Learning and Memory. Mol Biol Evol. 21: 2111-5.

Magklara A, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Danese S,Diamandis EP. (2001) The Human KLK8 (Neuropsin/Ovasin) Gene: Identification of Two Novel Splice Variants and Its Prognostic Value in Ovarian Cancer. Clin Cancer Res. 7: 806-11.

Matsui T, Hamako J, Matsushita T, Nakayama T, Fujimura Y, Titani K (2002). Binding site on human von Willebrand factor of bitiscetin, a snake venom-derived platelet aggregation inducer. Biochemistry. 41: 7939-46.

Matsumoto-Miyai K, Ninomiya A, Yamasaki H, Tamura H, Nakamura Y, Shiosaka S (2003) NMDA-Dependent Proteolysis of Presynaptic Adhesion Molecule L1 in the Hippocampus by Neuropsin. J Neurosci. 23: 7727-36.

Mitsui S, Tsuruoka N, Yamashiro K, Nakazato H, Yamaguchi N (1999) A novel form of human neuropsin, a brain-related serine protease, is generated by alternative splicing and is expressed preferentially in human adult brain. Eur J Biochem. pp 260 : 627-34.

Momota Y, Yoshida S, Ito J, Shibata M, Kato K, Sakurai K, Matsumoto K, Shiosaka S. (1998). Blockade of neuropsin, a serine-protease, ameliorates kindling epilepsy. Eur J Neurosci. 10: 760-4.

Nakamura Y,Tamura H, Horinouchi K, Shiosaka S (2006). Role of neuropsin in formation and maturation of

Schaffer- collateral L1cam-immunoreactive synaptic boutons. J Cell Sci 119: Pt7. 1341-1349.

Ogawa T, Chijiwa T, Oda-Ueda N, Ohno M (2005). Molecular diversity and accelerated evolution of C-type lectin-like proteins from snake venom. Toxicon. 45: 1-14.

Oka T, Hakoshima T, Itakura M, Yamamori S, Takahashi M, Hashimoto Y, Shiosaka S,Kato K. (2002) Role of Loop Structures of Neuropsin in the Activity of Serine Protease and Regulated Secretion. J Biol Chem. 277: 14724-30.

Okabe A, Momota Y, Yoshida S, Hirata A, Ito J, Nishino H, Shiosaka S. (1996). Kindling induces neuropsin mRNA in mouse brain. Brain Res. 728: 116-20

Perona JJ, Craik CS (1995). Structural basis of substrate specificity in the serine proteases. Protein Sci. 4: 337-60. Perona JJ, Craik CS (1997). Evolutionary divergence of substrate specifity within the chymotrypsin-like serine protease fold. J Biol Chem. 272: 29987-90.

Perona JJ, Hedstrom L, Rutter WJ, Fletterick RJ. (1995). Structural origins of substrate discrimination in trypsin and chymotrypsin. Biochemistry. 34: 1489-99.

Perona, JJ, Tsu CA, McGrath M.E, Craik CS, Fletterick RJ (1993). Relocating a negative charge in the binding pocket of trypsin. J Mol Biol. 230: 934-49.

Rao MB, Tanksale AM, Ghatge MS, Deshpande VV (1998). Molecular and biotechnological aspects of microbial proteases. Microbiol Mol Biol Rev. 62: 597-635.

Selkoe DJ. (1991). The molecular pathology of Alzheimer's disease. Neuron. 6: 487-98.

Sharp K, Honig B. (1999). Electrostatic interactions in macromolecules: Theory and applications. Annu Rev Biophys Chem 19:301-332.

Shimizu C, Yoshida S, Shibata M, Kato K, Momota Y, Matsumoto K, et al. (1998). Characterization of Recombinant and Brain Neuropsin, a Plasticity-related Serine Protease. J Biol Chem. 273: 11189-96.

Shimizu-Okabe C, Yousef GM, Diamandis EP, Yoshida S, Shiosaka S, Fahnestock M (2001). Expression of the kallikrein gene family in normal and Alzheimer's disease brain. NeuroReport. 12: 2747-51.

Shiosaka S (2004). Serine proteases regulating synaptic plasticity. Anato Sci Int. 79: 137-44.

Suzuki J, Yoshida S, Chen Z, Momota Y, Kato K, Hirata A, et al. (1995). Ontogeny of neuropisn RNAm expressionin the mouse brain. Neurosci Res. 23: 345-51.

Takahashi N, Tsukamoto Y, Shiosaka S, Kishi T, Hakoshima T, Arata Y, et al. (1999). N-glycan structures of murine hippocampus serine protease, neuropsin, produced in Trichoplusia ni cells. Glycoconj J. 16: 405-14.

Tamura H, Ishikawa Y, Hino N, Maeda M, Yoshida S, Kaku S, Shiosaka S (2006). Neuropsin is essential for

Tani N, Matsumoto K, Ota I, Yoshida S, Takada Y, Shiosaka S, et al. (2001). Effects of fibronectin cleaved by neuropsin on cell adhesion and migration. Neurosci Res. 39: 247-51.

Terayama R, Bando Y, Yamada M, Yoshida S (2005). Involvement of neuropsin in the pathogenesis of experimental autoimmune encephalomyelitis. Glia. 52(2):108-18.

Tomizawa K, He X, Yamanaka H, Shiosaka S, Yoshida S (1999). Injury induces neuropsin RNAm in the central nervous system. S Brain Res. 824: 308-11.

Underwood LJ, Tanimoto H, Wang Y, Shigemasa K, Parmley TH, O'Brien TJ. (1999). Cloning of Tumorassociated Differentially Expressed Gene-14, a Novel Serine Protease Overexpressed by Ovarian Carcinoma. Cancer Res. 59: 4435-9.

Wang Y, Luo W, Reiser G (2008). Trypsin and trypsin-like proteases in the brain: proteolysis and cellular functions. Cell Mol Life Sci. 65(2):237-52.

Yoshida S, Hirata A, Inoue N, Shiosaka S (2000). Assignment of the neuropsin gene (Prss19) to mouse chromosome band 7B4 by in situ hybridization. Cyto Cell Genet. 88: 97-8.

Yoshida S, Taniguchi M, Hirata A, Shiosaka S (1998). Sequence analysis and expression of human neuropsin cDNA and gene. Gene. 213: 9-16.

Yousef GM, Diamandis EP (2001). The New Human Tissue Kallikrein Gene Family: Structure, Function, an Association to Disease. Endocr Rev. 22: 184-204.

Yousef GM, Kishi T, Diamandis E P (2003). Role of kallikrein enzymes in the central nervous system. Clin Chim Acta. 329: 1-8.

Zeslawska E, Schweinitz A, Karcher A, Sondermann P, Sperl S, Sturzebecher J, Jacob U (2000). Crystals of the Urokinase Type Plasminogen Activator Variant bc-uPA in Complex with Small Molecule Inhibitors Open the Way towards Structure-based Drug Design. J. Mol. Biol. 301: 465-475.